Aerovate Current Deferred Revenue vs Long Term Debt Analysis
| AVTE Stock | USD 2.66 0.05 1.92% |
Aerovate Therapeutics financial indicator trend analysis is way more than just evaluating Aerovate Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aerovate Therapeutics is a good investment. Please check the relationship between Aerovate Therapeutics Current Deferred Revenue and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
Current Deferred Revenue vs Long Term Debt
Current Deferred Revenue vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aerovate Therapeutics Current Deferred Revenue account and Long Term Debt. At this time, the significance of the direction appears to have totally related.
The correlation between Aerovate Therapeutics' Current Deferred Revenue and Long Term Debt is 1.0. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Aerovate Therapeutics, assuming nothing else is changed. The correlation between historical values of Aerovate Therapeutics' Current Deferred Revenue and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Aerovate Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Current Deferred Revenue i.e., Aerovate Therapeutics' Current Deferred Revenue and Long Term Debt go up and down completely randomly.
Correlation Coefficient | 1.0 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Long Term Debt
Long-term debt is a debt that Aerovate Therapeutics has held for over one year. Long-term debt appears on Aerovate Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Aerovate Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from Aerovate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aerovate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.At present, Aerovate Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting.
| 2022 | 2023 | 2024 (projected) | Interest Income | 1.8M | 5.2M | 2.6M | Cost Of Revenue | 68K | 96K | 49.5K |
Aerovate Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Aerovate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.